Introduction {#S0001}
============

NPD is a heterogeneous disease with variations due to molecular and clinical courses. The incidence of the disease is approximately 1:150 000 live births^\[[@CIT0001]\]^. Because of variations in pathological and clinical features of the disease, NPD is classified into those with deficiency of acid sphingomyelinase activity (types A and B), and those with defective intracellular processing and transporting of LDL cholesterol, which is known as type C. However, NPD type C (NPC) is different at the biochemical and molecular levels with a higher incidence than NPA and NPB^\[[@CIT0002]\]^. Both types A and B are characterized by Acid sphingomyelinase (ASM) deficiency that leads to excessive sphingomyelin accumulation in all phagocytic cells and in neurons^\[[@CIT0003]\]^. NPB is biochemically similar to NPA, but with less severity^\[[@CIT0004]\]^. Normally, the enzyme activity of ASM leads to the breakdown of sphingomyelin into ceramide and phosphorylcholine in lysosomes^\[[@CIT0003]\]^. Generally, multiple organs such as spleen, liver, bone marrow, lymph nodes, lung and central nervous system are affected. Diagnosis can be achieved at the early childhood with a poor prognosis. Most NPA patients die before reaching the age of 3 years^\[[@CIT0001],\ [@CIT0003]\]^. Clinically, NPA is distinguished by failure of thrive, hepatosplenomegaly and progressive neurodegeneration^\[[@CIT0005]\]^. At molecular genetics level, mutations in the *SMPD1* gene on chromosome 11p14.5 are causative for the disease^\[[@CIT0006]\]^. The *SMPD1* gene is approximately 5 kb long and the coding sequence is divided among six exons. According to the Human Gene Mutation Database ([www.hmdb.cf.ac.uk](http://www.hmdb.cf.ac.uk)), more than 100 different mutations (including missense, nonsense, deletion, insertion, and splice site mutations) have been reported in the *SMPD1* gene.

To date, some clinical investigations have been reported from Iranian patients. For instance, Motamedi et al reported a case of NPB in Iran and described the clinical course of his patient^\[[@CIT0007]\]^. Furthermore, Motamed et al reported a ten year study of liver biopsies in children\'s Medical Center in Tehran. They identified numerous patients with storage diseases. Most identified patients were affected with NPD and glycogen storage disease type 1 (GSD-I)^\[[@CIT0008]\]^. In addition, Majidzadeh et al reported a case of NPD and compared clinical and molecular aspects of the disease^\[[@CIT0009]\]^. Hoshmand et al presented a novel mutation in the *SMPD1* gene (data not published). Here, we present the first molecular genetics diagnosis of NPA in an individual from southwest Iran.

Case Presentation {#S0002}
=================

A 2.5 year-old male, the first born child from first cousin parents was attending our center for genetic counseling and genetic diagnostics. The patient showed typical signs of the Niemann Pick disease, such as hepatosplenomegaly, developmental delay, mental retardation, and foam cells in the bone marrow, hypotonia, and cherry red maculae. Seizure and anorexia at 5-6^th^ month of life was observed. He died as results of his illness. Unfortunately, measurement of the ASM activity in the white blood cells failed and DNA test was the only chance to establish a definite diagnosis.

After obtaining informed consent, blood samples were collected from patient and his parents.

Genomic DNA was extracted from EDTA-anticoagulated whole blood by standard salting out procedures. Selective amplification of all 6 exons was performed in a volume of 25 µl reaction containing 10 pmol of each primer (TAG Copenhagen A/S, Fruebjergvej3, Denmark) and 50ng of genomic DNA. PCR was carried out by a set of designed primers using primer3out software (<http://frodo.wi.mit.edu/primer3/>). Properties of primers are indicated in [Table 1](#T0001){ref-type="table"}.

###### 

The *SMPD1* gene was amplified by seven primer pairs. Exon 2 was amplified by two separate primer pairs to assist subsequent sequencing reactions

  exon             Primer sequence (5\'to 3')   length   Tm
  ---------------- ---------------------------- -------- --------
  **1-forward**    GAAGCGCGACAATGCCCCGCTA       445 bp   60.5°C
  **1-reverse**    AGATGCCACCCTCTCCATCAGGGA              
  **2A-forward**   GTGTGCACTGAGCTTGGTGCACTG     493bp    60.3°C
  **2A-reverse**   GTCTGCACAGTCAGGGTCCGTG                
  **2B-forward**   TGCTGCCTGAGTTACAGGGCAA       1058bp   59.4°C
  **2B-reverse**   GCACTAAGGACTCATGCTAGAGCA              
  **3-forward**    GGCTAGACTGTGAGCTCCTTGCAG     441bp    59.1°C
  **3-reverse**    CAACAGTGACCATGAGCTGAATCC              
  **4-forward**    GTTGAGCTGGAGCACCTCTG         354bp    58.8°C
  **4-reverse**    CCCACTCCATGGGACAACAG                  
  **5-forward**    GACAGGGTGAGTGTCTGAAGGCTG     490bp    59.4°C
  **5-reverse**    GTACACACGGTAACCTGCAAGGA               
  **6-forward**    ACATCGGCCTTAATCCTGGTGAG      678bp    59.6°C
  **6-reverse**    ACCGGATGATCTTGCCTGGTTGAA              

Temperature profile of reactions were as follow: initial denaturation at 95°C for 3 min, 35 cycles of 95°C for 30s, 56-60°C for 30s and 72°C for 45s and a final extension at 72°C for 7 min. Direct sequencing of PCR products was carried out using ABI automated sequencer 3700 according to the manufacture\'s instruction (ABI 3700, PE Applied BioSystems, Foster City, CA, USA). Sequencing reactions were accomplished by the same primers that were used for exon amplification. Sequence analysis was performed with the software BioEdit (version 7.0.5.3). According to the human reference sequence NM_000543.4, a homozygous single guanine deletion, c.740delG, was observed in exon 2 of the *SMPD1* gene, which results in a premature stop codon (CTG\>TGA) between codons 256-257 (p.Gly247Alafs\*9) ([Fig. 1](#F0001){ref-type="fig"}). Apparently healthy parents were heterozygous for the detected change. They are also obligate carrier. To confirm the pathogenic relevance of the detected deletion, 27 healthy individuals were tested.

![Chromatogram of sequencing reactions from a) affected individual, b) heterozygote parents, c) healthy person. The location of the novel deletion is indicated with black arrow and the position of the resulting stop codon is shown in black circle on the chromatogram. At bottom (d), partial sequence of the *SMPD1* gene with corresponding codons is illustrated. Accordingly, the newly created stop codon is located between codons 256-257.](IJPD-23-233-g001){#F0001}

Discussion {#S0003}
==========

To our knowledge by intensive literature searching, the present report demonstrates firstly the molecular genetics diagnosis of the NPD in southwest Iran. Approximately 1 per 40,000 people of Ashkenazi Jewish descent has NPA^\[[@CIT0010]\]^. In contrast, there is no information about frequency and distribution of different types of NPD in Iran, particularly in southwest Iran.

The disease refers to a group of disorders with deficiency in lipid storage, causing accumulation of fats in brain and liver that lead to serious damage or dysfunction of mentioned tissues^\[[@CIT0011]\]^. However, liver enlargement, brain damage, difficulty in walking, speaking and learning are characteristic symptoms for NPA^\[[@CIT0012]\]^. Diagnosis of this type of disease is usually made by measuring the ASM activity in white blood cells^\[[@CIT0005]\]^. Regarding some typical symptoms, our patient was suspected to suffer of NPA. He was also referred to our molecular diagnostic center with the aim to find genetic cause of the disease. The *SMPD1* gene is the only gene considered to be associated with NPA^\[[@CIT0006]\]^.

Here, we report an unreported deletion of single guanine in exon 2 of the *SMPD1* gene, causing a truncated gene product. Exon 2 is unusually large, which encodes for 258 amino acids or approximately 44% of the entire ASM polypeptide. However, the pathogenic nature of the novel deletion was confirmed by screening of healthy individuals.

Three common missense mutations account for more than 90% of the mutant alleles in individuals of Ashkenazi Jewish ancestry with NPA. But in contrast to the Ashkenazi Jewish population, most affected individuals with NPA showed in previous studies unique mutations in the *SMPD1* gene^\[[@CIT0011]\]^. Consequently, identification of new NPA cases increases the probability to discover new specific mutations for the given population.

The present observations extend the mutation spectrum of the *SMPD1* gene in NPA patients worldwide, and can be used for the prenatal or preimplatation genetic diagnosis, at least in southwest Iran.

Conclusion {#S0004}
==========

To date, there are no hopeful therapeutic rudiments to cure NPA patients. Therefore, prevention seems to be more effective strategy in the next pregnancy for this family and other families with positive history.

Conflict of Interest {#S0005}
====================

None
